

Janet T. Mills
Governor

Sara Gagne- Holmes
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, June 10, 2025

Time: 6:00PM to 8:30PM

Location: **Virtual:**

To Dial in: 1-207-209-4724

Phone Conference ID: 386554688#

Teams link: [Join the meeting now](#)

In-Person:

109 Capitol Street

11 State House Station Rooms A and B

Augusta, Maine 04333

- 1) Closed Session (5:30pm - 6:00pm) - Board members only (a separate invitation to be sent)
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
- 5) Consent Agenda
 - Approve March 11, 2025, Meeting Minutes
 - New Cancer Medications: General CA category/class criteria is published on the MaineCare PDL
 - Aucatzyl
 - Datroway
 - Gomekli
 - Grafapex
 - Revuforj
 - Romvimza
 - Biosimilars
 - Bkernv (eculizumab-aeeb; biosimilar to Soliris)
 - Epysqli (eculizumab-aagh; biosimilar to Soliris)
 - Otulfi (ustekinumab-aaaz; biosimilar to Stelara)
 - Pyzchiva (ustekinumab-ttwe; biosimilar to Stelara)
 - Selarsdi (ustekinumab-aekn; biosimilar to Stelara)
 - Steqeyma (ustekinumab-stba; biosimilar to Stelara)
 - Yesintek (ustekinumab-kfce; biosimilar to Stelara)
- 6) Revised clinical criteria
 - None at this time
- 7) New Business (Open Session)
 - Retro DUR
 - Data Presentation: The effect of Hemlibra on the cost and quality of care in hemophilia A patients
 - Introduction: Biosimilar PDL cost saving evaluation
 - New/Revised Criteria
 - Antihemophilic Agents: Non-Factor Replacement Products
 - AADC Deficiency Agents
 - New Drug Review
 - Attruby
 - Inzirgo
 - Journavax
 - Kebilidi
 - Onapgo
 - Qfitlia
 - Raldesy
 - Tezruly
 - Tryngolza
 - Vanrafia
 - Vyalev
 - Xromi
 - Zunveyl
- 8) FDA Safety Alerts
 - FDA Requires Warning About Rare But Severe Itching After Stopping Long-Term Use of Oral Allergy Medicines Cetirizine or Levocetirizine (Zyrtec, Xyzal, and other trade names)
[FDA Safety Communication](#) – 05/16/2025
- 9) Next Meeting: Tuesday, September 9, 2025 | 6pm to 8:30pm
- 10) Adjournment: 8:30pm